Urovant Sciences

Improving quality of life through innovations in urology.

Vibegron

Our lead product candidate, vibegron, is an investigational oral, once-daily, small molecule beta-3 agonist, being developed for overactive bladder (OAB), OAB in men with benign prostatic hyperplasia (BPH) and pain associated with irritable bowel syndrome (IBS). We are currently evaluating vibegron in a pivotal Phase 3 international clinical trial for the treatment of OAB. We also plan to commence a Phase 3 clinical trial for OAB in men with BPH and a Phase 2a clinical trial for IBS-associated pain by the end of 2018.

LEARN MORE

women-sleeping

Latest News

The latest posts and articles

Urovant Sciences Ltd. Announces Pricing…

BASEL, Switzerland and IRVINE, Calif., September 26, 2018 /PRNewswire/ – Urovant Sciences Ltd. (Nasdaq: UROV),…

Kyorin Receives Approval from Japan’s…

Kyorin secures first commercial approval for vibegron Vibegron will be a new treatment option in…

Urovant Sciences Licenses Novel Gene…

There are no currently available FDA-approved gene therapy treatments for overactive bladder Urovant expects to…

Copyright 2018 © All Rights Reserved